Most Read Articles
Roshini Claire Anthony, 02 Dec 2020

People with HIV (PWH) who are hospitalized due to COVID-19 may have an increased mortality risk, according to a study from the UK.

21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Pearl Toh, 19 Dec 2020
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.
Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.

Poor physical performance raises red flag for CV hospitalization in COPD patients

06 Jan 2021

Patients with chronic obstructive pulmonary disorder (COPD) who perform poorly on the 6-min walk test (6MWT) are at increased risk of cardiovascular (CV)-related hospitalizations, a study has found.

The study involved 714 individuals (median age, 67 years; 61 percent male) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II–IV COPD. They smoked at least 10 pack years and were clinically stable for >4 weeks.

All patients underwent baseline assessments including aortic pulse wave velocity (aPWV), carotid intima–media thickness (CIMT), C-reactive protein (CRP), fibrinogen, spirometry, as well as Body mass index, airflow Obstruction, Dyspnoea and Exercise capacity (BODE) Index, 6MWT, and 4-min gait speed (4MGS) test.

Over a median follow-up of 4.6 years, 192 patients (27 percent) had a first event of CV hospitalization (peripheral arterial disease, diseases of arteries, arterioles and capillaries, angina, unstable angina, coronary heart disease, acute myocardial infarction, cerebral infarction, or stroke, among others). There were six CV deaths documented without any preceding CV episode. The overall CV incidence rate was 6.7 per 100 person-years.

Conventional CV risk factors had a C-statistic of 0.689 (95 percent confidence interval [CI], 0.688–0.691) in predicting CV outcomes in COPD. Both aPWV and CIMT had no association with fatal/nonfatal CV-related hospitalization, and neither did they improve model prediction.

On the other hand, CRP, fibrinogen, GOLD stage, BODE Index, 4MGS, and 6MWT were associated with the outcome, independently of conventional risk factors (p<0.05 for all). However, only 6MWT improved the predictive value of the conventional CV model (C, 0.727, 95 percent CI, 0.726–0.728).

These findings suggest that physical performance assessment may enhance CV risk evaluation in COPD patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 02 Dec 2020

People with HIV (PWH) who are hospitalized due to COVID-19 may have an increased mortality risk, according to a study from the UK.

21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Pearl Toh, 19 Dec 2020
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.
Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.